Absci Corp (ABSI) Stock Forecast & Price Target

Absci is supported by a differentiated AI-driven discovery engine that has already produced ABS-201 with improved affinity, extended half-life, and a high-concentration formulation, alongside interim PK data indicating an estimated half-life of at least 65 days that could enable only two or three injections over six months. The bull case is reinforced by a sizable unmet-need backdrop in hair loss and endometriosis, where 82% of surveyed respondents reported hair-loss concerns, 63% were likely to consider an infrequent injectable, and ABS-201’s hormone-independent PRLR mechanism has shown preclinical reductions in pain and inflammatory cytokines comparable to hormonal therapy. Financially, the thesis is underpinned by an rNPV framework valuing projected future revenues, with approximately $201M in net cash and equivalents and a pipeline strategy that prioritizes high-value internal assets for out-licensing, reducing reliance on broad target-stage collaborations.

Absci is viewed negatively because its pipeline remains in early stages, leaving no guarantee that ABS-201 or any other program will succeed clinically or reach regulatory approval, while competitive pressure from multiple AI drug-discovery peers and at least one PRLR rival raises execution risk. The company also faces meaningful funding risk, as expanding the discovery platform and advancing candidates through clinical trials will likely require additional capital, with no assurance that financing or partnerships will be available on favorable terms or continue to generate revenue. That dependency is especially concerning because the excerpt highlights serious adverse events and discontinuations in comparable hormone-related programs, underscoring how safety, regulatory scrutiny, and development uncertainty can erode investor confidence.